Brief: Akoustis Reports Fifth Consecutive Quarter Of Record Revenue As Second Quarter Fiscal 2023 Sales Grew Over 59% Year-Over-Year
Feb 7 (Reuters) - Akoustis Technologies Inc AKTS.O :
* AKOUSTIS REPORTS FIFTH CONSECUTIVE QUARTER OF RECORD
REVENUE AS
SECOND QUARTER FISCAL 2023 SALES GREW OVER 59% YEAR-OVER-YEAR
* QUARTERLY REVENUE ROSE 59 PERCENT TO $5.9 MILLION
* QTRLY NET LOSS PER COMMON SHARE - BASIC AND DILUTED $0.19
* Q2 EARNINGS PER SHARE VIEW $-0.25, REVENUE VIEW $5.9
MILLION --
REFINITIV IBES DATA
Source text for Eikon: ID:nGNX9gyn7G
Further company coverage: AKTS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aktis Oncology
See all newsAktis Oncology Q2 net loss widens on higher R&D, administrative costs
U.S. RESEARCH ROUNDUP-Danaher, GM, MSCI
Aktis Oncology Q1 net loss widens on increased IPO-related expenses
Generate Biomedicines shares fall 6% in weak Nasdaq debut for drug developer (updated)
Flagship-backed Generate Biomedicines shares fall 6% in Nasdaq debut